Hyalgan

Hyalgan is a prescription intra‑articular injection that contains sodium hyaluronate as its active ingredient; the product’s strength is not specified in the publicly available EU labeling. It is supplied as a sterile solution intended for direct injection into joints. Hyalgan belongs to the class of hyaluronic‑acid viscosupplements and is used to improve joint function by restoring the viscoelastic properties of synovial fluid in patients with osteoarthritis.

Hyalgan is indicated for the symptomatic treatment of osteoarthritis in several joints, where it is administered directly into the affected joint space.

- Knee osteoarthritis, providing intra‑articular supplementation of hyaluronic acid. - Hip osteoarthritis, used to improve joint mechanics and reduce pain. - Temporomandibular joint osteoarthritis, administered to enhance joint function. - As an adjunct to physical therapy or rehabilitation programs to support functional recovery. - In patients who have an inadequate response or contraindication to oral NSAIDs.

Adverse reactions to intra‑articular Hyalgan are generally related to the injection procedure and the product composition.

Common: - Transient pain or swelling at the injection site. - Mild warmth or flushing in the treated joint. - Temporary stiffness or reduced range of motion lasting a few days. - Low‑grade headache or fatigue.

Serious: - Acute joint infection (septic arthritis). - Allergic reaction presenting as rash, urticaria, or angioedema. - Persistent severe joint pain or effusion requiring medical evaluation. - Rare cases of tendon or ligament injury at the injection site.

Before using Hyalgan, clinicians should assess patient history and joint condition to minimize risks.

- Confirm diagnosis of osteoarthritis and rule out active joint infection. - Evaluate for hypersensitivity to hyaluronic acid or any component of the formulation. - Use caution in patients with bleeding disorders or those receiving anticoagulant therapy. - Consider alternative therapy for pregnant or nursing women, as safety data are limited. - Monitor for signs of infection or severe inflammation after each injection. - Avoid repeated injections in the same joint within a short interval without medical justification.

Hyalgan may interact with other agents that affect joint health or bleeding risk.

Avoid: - Concurrent intra‑articular corticosteroid injections in the same joint within a short period. - Use with intra‑articular antibiotics or other viscosupplements without physician guidance.

Use with caution: - Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to potential bleeding at the injection site. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase local irritation. - Disease‑modifying osteoarthritis drugs (DMOADs) where combined effects are not well studied. - High‑dose vitamin C or supplements that could affect cartilage metabolism.